In January, Sandoz spun out Nabriva Therapeutics to initiate clinical development of three classes of antibiotics. Using medicinal chemistry, Sandoz had created thousands of compounds derived from intermediates used in the manufacture of generic antibiotics, which were themselves active against bacteria.
Brunnerstraße 59
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
